Background. Early targeted antibiotic therapy is crucial when treating pediatric patients with bacteremia. While identification (ID) and antimicrobial susceptibility testing (AST) of bloodstream pathogens are critical to optimizing therapy, conventional methods can take days resulting in inappropriate use of broad-spectrum antibiotics. The automated Accelerate Pheno™ system (AXDX) provides ID in <90 minutes and AST in <7 hours directly from positive blood culture (PBC), enabling clinicians to optimize antibiotic therapy sooner to improve patient outcomes. In addition, the unique AXDX Monomicrobial call effectively rules out polymicrobial samples by indicating only one bacteria is present in the PBC. This study verifies AXDX performance compared with current laboratory ID and AST methods.
Methods.
A total of 54 pediatric PBC (33 spiked, 21 fresh) were tested within 8 hours of positivity 20 Gram-negative, 2 yeast, 2 off-panel species). A 0.5 mL aliquot was placed in an Accelerate PhenoTest™ BC kit sample vial and run on AXDX. Current laboratory methods for ID (Biofire Filmarray BCID, VITEK® 2, or MALDI-TOF) and AST (VITEK® 2 or Microscan) were run in parallel as comparators. Sensitivity (SN) and specificity (SP) were calculated for ID and essential (EA) and/or categorical agreement (CA), major (ME) and very major errors (VME) for AST. Positive predictive value (PPV) for the Monomicrobial call in fresh samples was calculated.
Results. Three samples were excluded (1 technical and 2 ID failures) and a total of 51 PBC samples were evaluated and analyzed. Following adjudication of discrepant results, AXDX demonstrated 100% SN and SP, with 97.7% EA and 96.8% CA compared with current laboratory methods. The single VME and 2 of 3 ME were adjudicated to AXDX. The two off-panel organisms did not result in ID or AST from AXDX. The PPV for the Monomicrobial call was 100%. Overall times to ID and AST were reduced by 18.5 hours and 31.2 hours, respectively.
Conclusion. The Accelerate Pheno™ system demonstrated high performance for both ID and AST of PBC much faster than current laboratory methods. Implementing this system will allow laboratories to provide clinicians with actionable results much sooner, enabling them to optimize therapy earlier to improve patient outcomes. Methods. MSDGN panels were evaluated for reproducibility at three sites. For reproducibility, a total of 17 on-scale organisms were tested on MSDGN panels at each site (14 Enterobacteriaceae and 3 Pseudomonas aeruginosa). Three replicates of each organism were tested each day for three days using the turbidity and Prompt TM* methods of inoculation. MSDGN panels were incubated at 35 ± 2°C and read on the WalkAway System, the autoSCAN-4 instrument, and read visually. Read times for the MSDGN panels were at 16-20 hours. FDA breakpoints (µg/mL) used for interpretation of MIC results were: Enterobacteriaceae ≤ 2/4 S, 4/4 I and ≥ 8/4 R; P. aeruginosa ≤ 4/4 S, 8/4 I and ≥16/4 R.
Results. Reproducibility among the three sites was greater than 95% for all read methods for both the turbidity and Prompt inoculation methods.
Conclusion. This multicenter study showed that Ceftolozane/ Tazobactam Materials/Methods. MSDGN panels were evaluated for reproducibility at three sites. For reproducibility, a total of 16 on-scale organisms were tested on MSDGN panels at each site (13 Enterobacteriaceae and 3 Pseudomonas aeruginosa). Three replicates of each organism were tested each day for three days using the turbidity and PromptTM* methods of inoculation. MSDGN panels were incubated at 35 ± 2°C and read on the WalkAway System, the autoSCAN-4 instrument, and read visually. Read times for the MSDGN panels were at 16-20 hours. FDA breakpoints (µg/mL) used for interpretation of MIC results were: Enterobacteriaceae ≤ 8/4 S and ≥ 16/4 R; P. aeruginosa ≤ 8/4 S and ≥ 16/4 R.
Conclusion Background. The current standard technique for diagnosis of bloodstream infection (BSI) is through the detection of micro-organisms using automated blood culture systems and subsequent phenotypic antimicrobial susceptibilty testing (AST) techniques that require 24-48 hours to generate results. The aim of this study was to evaluate the Accelerate Pheno™ system (AXDX), which utilises fluorescent in situ hybridization and morphokinetic cellular analysis to identify bacteria from positive blood cultures and perform AST in less than 7 hours.
Methods. The Accelerate PhenoTest™ BC kit was used to test 15 gram-negative isolates with a range of AST profiles, from simulated blood cultures. Isolates included 10 target organisms; Escherichia coli (n = 2), Enterobacter sp. (n = 2), Klebsiella sp., Proteus sp., Citrobacter sp., Pseudomonas aeruginosa, Acinetobacter baumannii, Serratia marcescens and 5 non-target organisms. AXDX results were compared with MALDI-ToF MS identification and BD Phoenix™ automated AST results. To evaluate the reproducibility of AXDX analysis, all isolates were tested at two different sites, six in duplicate.
Results. A total of 37 tests were performed. AXDX correctly identified 90% (9/10) of the target organisms, and correctly identified 100% (5/5) of non-target organisms as such. One isolate of Citrobacter sp. was initially misidentified as Enterobacter sp. but was correctly identified twice on repeat testing. The AST results demonstrated 93% (244/262) essential agreement (MIC within <1 dilution) and 90% (237/262) categorical agreement (same S/I/R interpretation) compared with conventional laboratory methods. For AST results, between-site reproducibility (MIC within <1 dilution) was 97%.
Conclusion. The Accelerate PhenoTest™ BC kit can provide rapid identification alongside phenotypic AST results direct from positive blood cultures. In this study, the assay demonstrated high reproducibility and good correlation with conventional laboratory methods. By reducing the time to AST results the Accelerate Pheno™ system has the potential to produce actionable results for the management of BSI and enable earlier escalation or de-escalation of antibiotic therapy. This also has the potential to improve patient outcomes by reducing morbidity and mortality. 
